Rising Specialty Ophthalmics And Biosimilars Will Open New Markets
AN
AnalystConsensusTarget
Not Invested
Consensus Narrative from 8 Analysts
Published
05 May 25
Updated
15 Aug 25
AnalystConsensusTarget's Fair Value
US$59.78
36.0% undervalued intrinsic discount15 Aug
US$38.23
1Y
-2.7%7D
9.8%